Diabetic Gastroparesis News

Metoclopramide Spray for Diabetic Gastroparesis On Track for Regulatory Approval - Gastroenterology & Endoscopy News



Metoclopramide Spray for Diabetic Gastroparesis On Track for Regulatory Approval 
Gastroenterology & Endoscopy News
A nasal metoclopramide spray is expected to become a new option for the treatment of diabetic gastroparesis. The spray, recently tested in a Phase III trial, avoids the problems of absorption inherent with an oral medication. Compared with the oral ...

 


Diabetic Gastroparesis Product Description, Developmental Activities, Licensors, Collaborators and Chemical Information - Medgadget (blog)



Diabetic Gastroparesis Product Description, Developmental Activities, Licensors, Collaborators and Chemical Information 
Medgadget (blog)
?Diabetic Gastroparesis-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Diabetic Gastroparesis. The report provides a complete understanding of the pipeline ...

and more » 


Gastroparesis Treatment Market is expected to grow at a CAGR of ~ 3.8% by 2023 - Industry Today (press release)



Gastroparesis Treatment Market is expected to grow at a CAGR of ~ 3.8% by 2023 
Industry Today (press release)
Prokinetic medications that stimulate gastric emptying, including metoclopramide, erythromycin, and domperidone, lead the drug segment. Although Idiopathic Gastroparesis leads the market share the Diabetic Gastroparesis is the fastest growing segment.

and more » 


Diabetic Gastroparesis Treatment Market to Amass Revenues More Than US$ 3769.3 Mn by 2024 - Medgadget (blog)



Medgadget (blog)
 
Diabetic Gastroparesis Treatment Market to Amass Revenues More Than US$ 3769.3 Mn by 2024 
Medgadget (blog)
According to the latest market report published by Persistence Market Research titled ?Diabetic Gastroparesis Treatment Market: Global Industry Analysis and Forecast, 2016 ? 2024?, revenue from the global diabetic gastroparesis treatment market is ...

and more » 


Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference - GlobeNewswire (press release)



Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference 
GlobeNewswire (press release)
The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a disorder afflicting millions of sufferers worldwide ...

and more » 


Is Apple Cider Vinegar Safe to Drink? - Care2.com



Care2.com
 
Is Apple Cider Vinegar Safe to Drink? 
Care2.com
Third, if you suffer from a diabetic condition known as gastroparesis (which is condition of the stomach in which the nerves do not properly work, resulting in food staying in the stomach for excessive periods) than you are better off not drinking ...

 


Diabetic Gastroparesis Treatment Market Is Expected To Register A CAGR Of 4.1% Over The Forecast Period 2016?2024 - MilTech



Diabetic Gastroparesis Treatment Market Is Expected To Register A CAGR Of 4.1% Over The Forecast Period 2016?2024 
MilTech
Rising prevalence of Type-1 and Type-2 diabetes with high unmet medical needs, growing demand for minimally invasive treatment for refractory gastroparesis, and availability of reimbursement for in-patient hospital stays are driving growth of the ...

and more » 


Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open - Endpoints News



Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open 
Endpoints News
... Third Rock Ventures, Ipsen, Pfizer Venture Investments, OrbiMed and Deerfield Management. Late last year Allergan struck a deal to buy Motus Therapeutics, a subsidiary of Rhythm Holding which controlled its diabetic gastroparesis treatment relamorelin.

and more » 


Evoke Pharma, Inc. (NASDAQ:EVOK) Stock Traded Well Above Its 50 Day Moving Average - First News 24



MoneyMakingArticles
 
Evoke Pharma, Inc. (NASDAQ:EVOK) Stock Traded Well Above Its 50 Day Moving Average 
First News 24
The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of ...
EPS for Evoke Pharma (EVOK) Expected At $-0.15; Pennantpark Investment (PNNT)'s Sentiment Is 1.41 MoneyMakingArticles
Next Weeks Broker Price Targets For Evoke Pharma, Inc. (EVOK ... Fiscal Standard

all 5 news articles » 


This is what analysts have to say about Evoke Pharma Inc (NASDAQ:EVOK) after last week. - BZ Weekly



Press Telegraph
 
This is what analysts have to say about Evoke Pharma Inc (NASDAQ:EVOK) after last week. 
BZ Weekly
Investors sentiment decreased to 1.5 in 2017 Q2. Its down 3.83, from 5.33 in 2017Q1. It is negative, as 1 investors sold Evoke Pharma Inc shares while 3 reduced holdings. 1 funds opened positions while 5 raised stakes. 1.88 million shares or 44.66 ...
Evoke Pharma Inc (EVOK) Analysts See $-0.15 EPS - The Weekly Hub WeeklyHub
Analysts Set Evoke Pharma, Inc. (EVOK) PT at $8.50 - Week Herald Week Herald
Zacks Investment Research Upgrades Evoke Pharma, Inc. (EVOK ... BBNS
The Ledger Gazette  -Zacks Investment Research 
all 14 news articles »